According to TechCrunch, AI oncology platform Triomics closed a $22 million Series B round on May 28, led by Battery Ventures. Nexus Venture Partners, Lightspeed, and Y Combinator participated as existing investors.
Triomics develops an AI-driven platform to help oncologists and administrative staff automate clinical trial matching and appointment preparation. The company, founded in 2021, previously raised $15 million in Series A funding in mid-2024 and has since expanded its platform capabilities, including verifiable patient summary features integrated directly into existing clinical tools.